Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
Press Release (News)
, Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a.., Press Release (News)
EMPATHY Part A RCT with 407 patients, 301 treated with ensovibep, showing statistically significant viral load reduction (details not provided), and lower mortality and hospitalization. For discussion see [twitter.com].
|
risk of death, 89.0% lower, RR 0.11, p = 0.06, treatment 0 of 301 (0.0%), control 2 of 99 (2.0%), NNT 49, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
|
risk of hospitalization, 86.8% lower, RR 0.13, p = 0.01, treatment 2 of 301 (0.7%), control 5 of 99 (5.1%), NNT 23.
|
|
risk of hospitalization/ER, 78.1% lower, RR 0.22, p = 0.02, treatment 4 of 301 (1.3%), control 6 of 99 (6.1%), NNT 21.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Novartis et al., 10 Jan 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author.
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.